Drug or treatment

Nivolumab clinical trials

• 149Clinical trials
• 50Countries

Newest trials

All recruiting trials (149)

• Intratumoral fluorescent nivolumab before surgery in head and neck cancer

  This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741565

• Bexmarilimab plus nivolumab in solid tumors, melanoma, and NSCLC

  This trial tests whether adding bexmarilimab to nivolumab can help people with melanoma, non-small cell lung cancer, or other advanced solid tumors whose cancer stopped responding to immune therapy.

  Recruiting at 2 sites Phase 1/2 Institute of Cancer Research, United Kingdom · Manchester and 1 other locations · NCT07718243

• Cadonilimab with chemotherapy vs chemotherapy with/without nivolumab as first-line treatment for HER2-negative advanced gastric/GEJ cancer

  This study tests whether adding cadonilimab to chemotherapy helps people with newly diagnosed, unresectable or metastatic HER2-negative gastric/GEJ cancer live longer, compared with standard chemo alone (with or without nivolumab).

  Recruiting Phase 3 Akeso · Phoenix, Arizona and 24 other locations · NCT07700979

• Dendritic Cell Vaccine with HER2-targeted Therapy or Nivolumab for Breast Cancer with Leptomeningeal Metastasis

  This trial tests a dendritic cell vaccine added to trastuzumab for Her2-positive disease or to nivolumab for Her2-negative disease to see if it can be given safely to people with breast cancer that has spread to the leptomeninges.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07694986

• First-Line Nivolumab plus Ipilimumab in unresectable hepatocellular carcinoma

  This study tests whether the combination of nivolumab and ipilimumab is safe and effective for adults with unresectable liver cancer in real-world care in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07679061

• Neuro-navigation-guided focused ultrasound with nivolumab for relapsed or progressive high-grade brain tumors in children

  This study tests whether using focused ultrasound to open the blood-brain barrier and give nivolumab is safe and feasible for kids with relapsed or progressive DMG/DIPG or other high-grade brain tumors.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia · NCT07664176

• Brachytherapy and Nivolumab Before Surgery for Rectal Cancer

  This small Phase II study tests whether targeted internal radiation therapy followed by two doses of nivolumab can be safely given before rectal cancer surgery to see if it helps the treatment work.

  Recruiting Phase 2 Sir Mortimer B. Davis - Jewish General Hospital · Montreal, Quebec · NCT07645118

• Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

  This study tests whether adding axelopran to nivolumab can help people whose melanoma no longer responds to PD-1 therapy.

  Recruiting Phase 1/2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07631325

• 30-minute cycling immediately before nivolumab and ipilimumab for metastatic melanoma

  This trial will test whether a 30-minute cycling session immediately before nivolumab plus ipilimumab boosts immune activity and improves outcomes for people with metastatic melanoma.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg, Free and Hanseatic City of Hamburg · NCT07564570

• Nivolumab plus AVD for newly diagnosed early-stage non-bulky classical Hodgkin lymphoma in young patients

  This study tests whether nivolumab added to AVD can help children, teens, and young adults with newly diagnosed early-stage non-bulky Hodgkin lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07551583

• Ficerafusp alfa with nivolumab in platinum-refractory head and neck cancer

  This study tests whether adding ficerafusp alfa to nivolumab helps patients with head and neck squamous cell cancer that progressed after platinum therapy.

  Recruiting Phase 2 Groupe Oncologie Radiotherapie Tete et Cou · Villejuif · NCT07529873

• Denikitug (GS-1811) given alone or with nivolumab or with chemotherapy for advanced colorectal cancer

  This study tests Denikitug alone and in combination with nivolumab or with chemotherapy for adults whose colorectal cancer is advanced and MSS.

  Recruiting at 8 sites Phase 2 Gilead Sciences · North Haven, Connecticut and 14 other locations · NCT07527858

• VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma

  This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07510334

• Using ctDNA to decide whether to add ipilimumab for people on nivolumab and relatlimab

  This tests whether using a ctDNA blood test to guide adding ipilimumab for adults with advanced or metastatic melanoma on nivolumab and relatlimab leads to longer progression-free survival.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07504796

• Neoadjuvant immunotherapy for high-risk eye melanoma

  This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07501117

• Y90 liver radiation plus immunotherapy and targeted drug for unresectable liver cancer

  This test will see if adding Y90 liver radiation to nivolumab, ipilimumab, and lenvatinib helps people with unresectable hepatocellular carcinoma live longer and have better tumor responses.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07482059

• Nivolumab-IRDyE800CW imaging agent used before surgery in head and neck cancer

  This early-stage trial tests whether nivolumab labeled with IRDye800CW can safely be given before surgery to see if it helps image head and neck squamous cell carcinoma.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07460765

• Pazopanib added to a multi-drug regimen for kids and young adults with recurrent soft tissue sarcomas

  This study tests whether adding pazopanib to a regimen of trabectedin, ipilimumab, and nivolumab is safe and possibly beneficial for children and young adults with recurrent soft tissue sarcomas.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07444619

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• DNAJB1-PRKACA vaccine plus DRP-104, nivolumab, and ipilimumab for advanced fibrolamellar liver cancer

  A early-stage study tests whether a personalized vaccine plus two immune drugs and a glutamine-blocking agent can safely help people with advanced fibrolamellar liver cancer.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07430202

• Serplulimab versus nivolumab with chemotherapy before surgery for resectable stage II–IIIA squamous lung cancer

  This study will test whether giving serplulimab plus chemotherapy before surgery works better than nivolumab plus chemotherapy in adults with resectable stage II–IIIA squamous non-small cell lung cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07398937

• Comparing chemo‑immunotherapy options for metastatic NSCLC with PD‑L1 <50%

  This project will see if two common first‑line chemo‑immunotherapy approaches give different survival and quality‑of‑life results for adults with metastatic NSCLC whose tumors have PD‑L1 under 50%.

  Recruiting at 2 sites Gazi University · Ankara and 1 other locations · NCT07394062

• TGI-5 alone and with nivolumab for advanced or metastatic solid tumors

  This trial tests whether TGI-5 by itself or combined with nivolumab is safe and can shrink tumors in adults with advanced or metastatic colorectal cancer, melanoma, hepatocellular carcinoma, or non‑small cell lung cancer who have exhausted standard treatments.

  Recruiting Phase 1 Hefei TG ImmunoPharma Co., Ltd. · Shanghai · NCT07376707

• Large granular lymphocytes in metastatic non-small cell lung cancer treated with nivolumab

  This study will test whether the percentage of large granular lymphocytes in the blood at baseline and after three months can predict response to nivolumab in people with metastatic non-small cell lung cancer receiving it as second-line therapy.

  Recruiting Necmettin Erbakan University · Konya, Meram · NCT07363811

• First-Line Ipilimumab, Nivolumab, and IL-15 Superagonist in Advanced or Recurrent NSCLC

  A phase Ib/II study tests whether adding nogapendekin alfa inbakicept to nivolumab and ipilimumab helps people with stage IV or recurrent non-small cell lung cancer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07355205

• COLONYVAQ™: personalized quantum‑classical neoantigen peptide vaccine combined with chemotherapy and nivolumab for MSS stage III colorectal cancer

  This trial will test a personalized neoantigen peptide vaccine guided by quantum‑classical AI together with standard oxaliplatin‑based chemotherapy and nivolumab in patients with completely resected, microsatellite‑stable stage III colorectal cancer.

  Recruiting Early Phase 1 Biogenea Pharmaceuticals Ltd. · Thessaloniki · NCT07328087

• HEPZATO KIT with Opdualag for metastatic melanoma that has spread to the liver

  This will try adding HEPZATO KIT to Opdualag (nivolumab + relatlimab) to see if it's safe and helps people with metastatic melanoma that has spread to the liver.

  Recruiting Phase 1/2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07281924

• Nenocorilant plus nivolumab for advanced solid tumors

  This trial tests whether adding the oral drug nenocorilant to nivolumab is safe and can identify the best dose for people with advanced solid tumors.

  Recruiting at 5 sites Phase 1/2 Corcept Therapeutics · Los Angeles, California and 4 other locations · NCT07276373

• Visugromab plus nivolumab, with or without docetaxel, for second-line treatment of metastatic non-squamous non-small cell lung cancer

  This trial tests whether adding the anti-GDF-15 antibody visugromab to nivolumab, with or without docetaxel, helps people with metastatic non-squamous NSCLC whose cancer progressed after first-line treatment that included a checkpoint inhibitor.

  Recruiting at 36 sites Phase 2 CatalYm GmbH · Birmingham, Alabama and 35 other locations · NCT07246863

• Nivolumab with AVD versus PET-adapted BEACOPP-like for advanced classical Hodgkin lymphoma

  This trial will test whether starting treatment with low-dose nivolumab plus AVD works better than a PET-adapted BEACOPP-like approach for adults (18–60) with advanced classical Hodgkin lymphoma.

  Recruiting at 3 sites Phase 2 St. Petersburg State Pavlov Medical University · Moscow and 2 other locations · NCT07234487

• BMS-986340 with nivolumab plus gemcitabine and nab-paclitaxel for advanced or recurrent pancreatic adenocarcinoma

  This trial tests whether adding the antibody BMS-986340 to nivolumab together with gemcitabine and nab-paclitaxel helps people with metastatic or recurrent pancreatic adenocarcinoma.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT07226856

• Comparing two immunotherapy combinations and their immune effects in unresectable or metastatic melanoma

  This will test whether two different first-line immunotherapy combinations produce different immune responses in tumors and blood of people with unresectable or metastatic melanoma.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223411

• MB11 versus Opdivo for previously untreated advanced (unresectable or metastatic) melanoma

  This trial will test whether MB11, a proposed nivolumab biosimilar, works like EU- or US-sourced Opdivo for adults with untreated advanced (unresectable or metastatic) melanoma.

  Recruiting at 86 sites Phase 3 mAbxience Research S.L. · Banja Luka and 85 other locations · NCT07221734

• Pumitamig plus chemotherapy versus nivolumab plus chemotherapy for untreated advanced gastric, gastroesophageal junction, or distal esophageal adenocarcinoma

  This trial will try Pumitamig with chemotherapy versus nivolumab with chemotherapy in people with previously untreated advanced or metastatic gastric, gastroesophageal junction, or distal esophageal adenocarcinoma.

  Recruiting at 106 sites Phase 2/3 Bristol-Myers Squibb · Phoenix, Arizona and 160 other locations · NCT07221149

• Visugromab plus Nivolumab and Lenvatinib versus Placebo plus Lenvatinib for unresectable or metastatic hepatocellular carcinoma after anti–PD-(L)1 therapy

  This trial will test whether adding visugromab and nivolumab to lenvatinib helps people with unresectable or metastatic liver cancer whose disease progressed after an anti–PD-(L)1 treatment.

  Recruiting at 29 sites Phase 2 CatalYm GmbH · Irvine, California and 28 other locations · NCT07219459

• Adding simvastatin to nivolumab and oxaliplatin-based chemotherapy for ARID1A‑mutated advanced gastroesophageal cancer

  This trial will test whether adding daily simvastatin to nivolumab plus oxaliplatin-based chemotherapy helps people with HER2-negative, ARID1A-mutated advanced gastroesophageal cancer stay progression-free longer.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples, Italia · NCT07213557

• Fluorescent-labeled nivolumab (Nivo800) imaging for high-grade glioma surgery

  This trial tests whether a near-infrared fluorescent version of the immunotherapy drug nivolumab can be given before planned surgery to visualize drug distribution in adults with suspected high-grade glioma.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07210632

• PET-guided first-line nivolumab plus chemotherapy for advanced Hodgkin lymphoma

  This pilot trial tests whether adding nivolumab to initial chemotherapy and changing treatment based on an early PET scan helps adults with advanced classical Hodgkin lymphoma.

  Recruiting Phase 2 National Research Center for Hematology, Russia · Moscow · NCT07209059

• First-line nivolumab plus ipilimumab with short-course chemotherapy for metastatic non-small cell lung cancer

  This project will collect real-world data to see if nivolumab plus ipilimumab combined with a short course of platinum chemotherapy works well as first-line treatment for adults with metastatic non-small cell lung cancer who do not have EGFR or ALK alterations.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07190677

• First-line immune-checkpoint antibody combinations for advanced clear cell kidney cancer

  This trial tests whether combining fianlimab and cemiplimab, with or without ipilimumab, works better than the standard ipilimumab plus nivolumab as first treatment for people with advanced clear cell kidney cancer.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · Washington D.C., District of Columbia and 4 other locations · NCT07188896

• Nivolumab with chemotherapy as neoadjuvant therapy for resectable NSCLC in Taiwan

  This real-world study tests whether adding nivolumab to chemotherapy before surgery helps people with NSCLC in Taiwan.

  Recruiting at 9 sites Ono Pharmaceutical Co., Ltd. · Kaohsiung City and 8 other locations · NCT07169708

• Guided high‑dose‑rate esophageal brachytherapy with radiotherapy and nivolumab for esophageal squamous cell carcinoma

  We will test whether adding a guided high‑dose‑rate (HDR) esophageal brachytherapy session to prior radiotherapy, chemotherapy, and nivolumab helps people with locally advanced esophageal squamous cell carcinoma lower the chance the tumor returns near the esophagus within 12 months.

  Recruiting Phase 2 National Taiwan University Hospital · Huwei, Yunlin County · NCT07152678

• Lenvatinib with nivolumab and chemotherapy for metastatic gastric cancer with malignant ascites

  This trial tests whether adding lenvatinib to nivolumab plus chemotherapy helps people with metastatic gastric or gastroesophageal junction adenocarcinoma who have peritoneal metastases and significant malignant ascites.

  Recruiting Phase 1/2 Asan Medical Center · Seoul · NCT07149090

• Nivolumab and ipilimumab with or without EXL01 for advanced or metastatic clear-cell and sarcomatoid renal cell carcinoma

  This trial tests whether adding EXL01, a live Faecalibacterium prausnitzii product, to nivolumab and ipilimumab helps adults with advanced or metastatic clear-cell or sarcomatoid renal cell cancer.

  Recruiting at 2 sites Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07128680

• Nivolumab for recurrent or metastatic olfactory neuroblastoma

  This trial will try nivolumab, a PD‑1 immunotherapy, in adults with recurrent or metastatic olfactory neuroblastoma to see if it controls tumor growth and is safe.

  Recruiting at 2 sites Phase 2 National Cancer Center Hospital East · Kashiwa, Chiba and 1 other locations · NCT07100704

• Ipilimumab and nivolumab plus focused liver radiation for locally advanced liver cancer

  This trial tests whether combining nivolumab and ipilimumab with focused liver radiation (SBRT) can help adults with locally advanced hepatocellular carcinoma, with attention to including Native Hawaiian and Pacific Islander patients.

  Recruiting Phase 1 University of Hawaii · Honolulu, Hawaii and 1 other locations · NCT07075120

• Low‑dose nivolumab plus chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer

  This trial tests whether adding low‑dose nivolumab to standard chemotherapy helps people with advanced or metastatic non‑small cell lung cancer starting first‑line treatment.

  Recruiting Phase 3 Hospital Sultanah Bahiyah · Alor Star, Kedah · NCT07050043

• Digital symptom monitoring for people starting cabozantinib plus nivolumab for advanced clear-cell kidney cancer

  This project tests whether weekly digital self-reports of symptoms can help guide treatment management for adults beginning cabozantinib plus nivolumab for advanced clear-cell kidney cancer during the first three months.

  Recruiting at 3 sites Phase 4 Centre Francois Baclesse · Annecy and 18 other locations · NCT07028125

• Neoadjuvant ipilimumab, relatlimab, and nivolumab combinations for resectable cutaneous and mucosal melanoma

  This phase 2 trial will test several immunotherapy combinations given before surgery to try to reduce recurrence in adults with resectable stage 3 cutaneous melanoma or resectable mucosal melanoma, including patients predicted or known to respond poorly to standard anti‑PD‑1 therapy.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06999980

• Using nivolumab with AVD for advanced Hodgkin lymphoma

  This study is testing if a new combination of nivolumab and AVD chemotherapy can help people with newly diagnosed advanced Hodgkin lymphoma feel better and respond well to treatment.

  Recruiting Phase 2 National Medical Research Radiological Centre of the Ministry of Health of Russia · Moscow · NCT06984146

• Combination treatment for advanced urothelial carcinoma

  This study is testing a new combination of a drug called AM80 with standard chemotherapy and immunotherapy to see if it helps people with advanced bladder cancer feel better and live longer.

  Recruiting Phase 2 Nagoya University · Nagoya, Aichi-ken · NCT06983210

• Sacituzumab govitecan with nivolumab, with or without relatlimab, for metastatic triple-negative breast cancer

  This trial tests whether adding nivolumab alone or nivolumab plus relatlimab to sacituzumab govitecan helps people with metastatic triple-negative breast cancer who have had one prior line of chemotherapy.

  Recruiting Phase 1/2 Yale University · New Haven, Connecticut · NCT06963905

• Nivolumab plus cabozantinib for older adults with kidney cancer

  This trial tests the combination of nivolumab and cabozantinib in people aged 70 and older with metastatic clear-cell kidney cancer to see how it is used and tolerated in routine care.

  Recruiting Phase 4 Gustave Roussy, Cancer Campus, Grand Paris · Angers and 6 other locations · NCT06934057

• Combination of nivolumab and ipilimumab before surgery for lung cancer

  This study is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery to see if it helps people with advanced lung cancer do better than traditional treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University · Guangzhou · NCT06926790

• Treatment of refractory non-squamous non-small cell lung cancer with leptomeningeal metastases using Pemetrexed and Nivolumab injections

  This study is testing if a combination of Pemetrexed and Nivolumab injections can help people with tough-to-treat lung cancer that has spread to the protective layers around the brain.

  Recruiting Phase 2 Shanghai Cancer Hospital, China · Shanghai, Shanghai Municipality · NCT06901817

• Testing a new treatment for advanced neuroendocrine tumors

  This study is testing a new treatment combining a virus with two cancer drugs to see if it helps people with advanced neuroendocrine tumors feel better and tolerate the treatment well.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT06889493

• Inulin gel plus ipilimumab and nivolumab for advanced kidney (renal cell) cancer

  This trial tests whether adding an inulin gel to the immunotherapy drugs ipilimumab and nivolumab helps people with locally advanced or metastatic clear cell or sarcomatoid renal cell carcinoma.

  Recruiting Phase 1/2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT06866262

• Nivolumab with or without relatlimab for newly diagnosed IDH‑wildtype glioblastoma

  This trial will test whether giving nivolumab alone or together with relatlimab around surgery helps adults with newly diagnosed IDH‑wildtype glioblastoma.

  Recruiting at 4 sites Phase 2 Duke University · New York, New York and 3 other locations · NCT06816927

• Zanzalintinib plus nivolumab before surgery for advanced clear cell kidney cancer

  This will try daily oral zanzalintinib together with regular nivolumab infusions for 12 weeks in adults with locally advanced or inoperable clear cell kidney cancer to shrink tumors and see if surgery becomes possible.

  Recruiting at 3 sites Phase 2 Hoosier Cancer Research Network · St Louis, Missouri and 3 other locations · NCT06794229

• Relatlimab, nivolumab, and ipilimumab for melanoma that has spread to the brain

  This trial will test whether the combination of relatlimab, nivolumab, and ipilimumab can help adults with melanoma brain metastases, including those with and without symptoms.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT06712927

• Triplet combination of Relatlimab, Nivolumab, and Ipilimumab in first-line metastatic melanoma

  A first-line trial tests whether a three-drug combo can help people with metastatic melanoma, starting at a recommended dose.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06683755

• Combination therapy for high-risk muscle-invasive bladder cancer

  This study is testing if a combination of two cancer drugs can help people with high-risk bladder cancer stay cancer-free after surgery.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06682728

• Comparing two treatments for extensive-stage small cell lung cancer

  This study is testing a new treatment combination for extensive-stage small cell lung cancer to see if it works better and is safer than the standard treatment.

  Recruiting at 18 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 182 other locations · NCT06646276

• Neoadjuvant Opdualag (nivolumab + relatlimab) versus nivolumab for resectable high-risk basal cell carcinoma

  This trial tests whether adding relatlimab to nivolumab before surgery helps people with resectable high‑risk basal cell carcinoma shrink tumors and improve surgical outcomes.

  Recruiting at 3 sites Phase 2 University of California, San Diego · Irvine, California and 2 other locations · NCT06624475

• Investigating RP2 and Nivolumab for Metastatic Uveal Melanoma

  This study is testing whether a new treatment combining RP2 with nivolumab can help adults with metastatic uveal melanoma feel better compared to the standard treatment of nivolumab and ipilimumab.

  Recruiting at 33 sites Phase 2/3 Replimune, Inc. · Scottsdale, Arizona and 32 other locations · NCT06581406

• Comparing two treatments for advanced non-small cell lung cancer

  This study is testing whether a combination of Nivolumab and Relatlimab with chemotherapy works better than Pembrolizumab with chemotherapy for people with advanced lung cancer.

  Recruiting at 239 sites Phase 3 Bristol-Myers Squibb · Mobile, Alabama and 329 other locations · NCT06561386

• Intralesional nivolumab for high-risk oral premalignant lesions

  This study tests if injecting a medication called nivolumab directly into high-risk oral lesions can help prevent the development of oral cancer in patients.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06561087

• Combination treatment for liver metastases from uveal melanoma

  This study is testing a new combination treatment for patients with liver metastases from uveal melanoma to see if adding a special delivery method can help them live longer without their cancer getting worse.

  Recruiting at 3 sites Phase 3 Vastra Gotaland Region · Gothenburg and 5 other locations · NCT06519266

• Combination treatment for advanced lung cancer with specific mutations

  This study is testing a new combination of medications for people with advanced lung cancer that has specific mutations and hasn't improved with other treatments, to see if it helps them live longer without the cancer getting worse.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 2 other locations · NCT06495125

• Combining EXL01 with Nivolumab for Advanced Lung Cancer

  This study is testing if combining a gut bacteria treatment with an immunotherapy drug can help people with advanced lung cancer who haven't had success with other treatments.

  Recruiting Phase 1/2 University Hospital, Lille · Lille · NCT06448572

• Probiotic effects on treatment response in lung cancer patients

  This study is testing whether a probiotic supplement can help lung cancer patients on immunotherapy respond better to their treatment.

  Recruiting Necmettin Erbakan University · Konya · NCT06428422

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Combining two immunotherapy drugs for MSI-H/dMMR advanced stomach and gastroesophageal junction cancer

  This trial will try two immunotherapy drugs (balstilimab and botensilimab) as first treatment for adults with MSI‑H/dMMR, HER2‑negative advanced or metastatic stomach or gastroesophageal‑junction cancer whose tumors have PD‑L1 CPS ≥5, and will compare that to standard chemotherapy with nivolumab.

  Recruiting at 7 sites Phase 3 Centre Leon Berard · Brest and 6 other locations · NCT06346197

• Neoadjuvant therapy using Nivolumab and Relatlimab for skin cancer

  This study is testing a new combination of two immunotherapy drugs, Nivolumab and Relatlimab, to see if they can help people with advanced skin cancer do better before surgery.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06288191

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• Comparing VO and Nivolumab to Standard Treatment for Advanced Melanoma

  This study is testing if a new combination of treatments, Vusolimogene Oderparepvec and nivolumab, can help people with advanced melanoma who haven't responded to other therapies feel better compared to standard treatments.

  Recruiting at 75 sites Phase 3 Replimune, Inc. · Gilbert, Arizona and 80 other locations · NCT06264180

• Combining EXL01 with Nivolumab and FOLFOX for treating advanced gastric cancer

  This study is testing a new combination of treatments for advanced gastric cancer to see if it works better than the standard treatment for patients with a specific level of a protein called PD-L1.

  Recruiting at 11 sites Phase 2 GERCOR - Multidisciplinary Oncology Cooperative Group · Angers and 36 other locations · NCT06253611

• Combining two experimental drugs for advanced melanoma treatment

  This study is testing if a new combination of two experimental drugs can help people with advanced melanoma more than the current approved treatments.

  Recruiting at 92 sites Phase 3 Regeneron Pharmaceuticals · Chandler, Arizona and 112 other locations · NCT06246916

• Local injection of ipilimumab and nivolumab for high-risk stage II melanoma

  This study is testing if injecting a combination of two immune-boosting drugs directly into the skin can help people with high-risk stage II melanoma by reducing the chance of cancer spreading.

  Recruiting at 2 sites Phase 1/2 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT06240143

• Combining Nivolumab with Standard Treatment for Advanced Stomach or Esophageal Cancer

  This study is testing if adding nivolumab to the usual treatments for advanced stomach or esophageal cancer can help patients live longer and feel better.

  Recruiting at 338 sites Phase 2/3 National Cancer Institute (NCI) · Little Rock, Arkansas and 377 other locations · NCT06203600

• Evaluating nivolumab with chemotherapy for early-stage lung cancer in Germany

  This study is testing whether combining nivolumab with chemotherapy can improve treatment outcomes for people in Germany with early-stage lung cancer that can be surgically removed.

  Recruiting Bristol-Myers Squibb · Kempten (Allgäu), Bavaria · NCT06169956

• Neoadjuvant immunotherapy for Merkel cell carcinoma

  This study is testing a combination of two immune treatments to see if they can help people with a type of skin cancer called Merkel cell carcinoma have better outcomes before surgery.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06151236

• Comparing two treatments for advanced melanoma

  This study is testing if a new combination treatment for advanced melanoma can work better than the standard treatment for patients who have not received treatment before.

  Recruiting at 201 sites Phase 3 Immunocore Ltd · Tucson, Arizona and 210 other locations · NCT06112314

• Using nivolumab with chemotherapy to treat nasopharyngeal carcinoma in young patients

  This study is testing if combining nivolumab with chemotherapy can help young patients with nasopharyngeal carcinoma live longer and feel better while reducing side effects from radiation.

  Recruiting at 84 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 85 other locations · NCT06064097

• Combining tivozanib and nivolumab for advanced non-clear cell kidney cancer

  This study tests if combining two medications, tivozanib and nivolumab, can help people with advanced non-clear cell kidney cancer manage their disease better.

  Recruiting at 6 sites Phase 2 M.D. Anderson Cancer Center · Irvine, California and 5 other locations · NCT06053658

• Adding a new drug to immunotherapy for advanced nasopharyngeal cancer

  This study is testing if adding a new drug to standard immunotherapy can help people with advanced nasopharyngeal cancer live longer and feel better after their initial treatment.

  Recruiting at 83 sites Phase 2 National Cancer Institute (NCI) · Dublin, California and 94 other locations · NCT06029270

• Using Nivolumab with chemotherapy for nasopharyngeal carcinoma in children and adults

  This study tests if adding the drug Nivolumab to regular chemotherapy can help children and adults with nasopharyngeal carcinoma respond better to treatment.

  Recruiting at 10 sites Phase 2 German Society for Pediatric Oncology and Hematology GPOH gGmbH · Aachen and 30 other locations · NCT06019130

• Combining Naltrexone and Propranolol with Immunotherapy for Advanced Melanoma

  This study is testing if combining two medications, naltrexone and propranolol, with immune therapy can help people with advanced melanoma feel better and improve their treatment results.

  Recruiting Phase 1 Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT05968690

• Nivolumab with chemotherapy for treating primary tracheal squamous cell carcinoma

  This study is testing whether combining a new immune therapy called Nivolumab with chemotherapy can help people with a rare type of throat cancer before surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05964101

• Using crizanlizumab alone or with nivolumab for treating advanced glioblastoma and melanoma with brain metastases

  This study is testing if a new treatment called crizanlizumab, alone or with another drug called nivolumab, can help people with advanced brain cancer from glioblastoma or melanoma that has spread to the brain.

  Recruiting Phase 2 Sheba Medical Center · Ramat Gan, Israel · NCT05909618

• Combining immunotherapy with prednisone and sirolimus for kidney transplant recipients with advanced skin cancer

  This study is testing a new treatment that combines two immunotherapy drugs with prednisone and sirolimus to see if it helps kidney transplant recipients with advanced skin cancer while keeping their transplanted kidney safe.

  Recruiting at 25 sites Phase 1/2 National Cancer Institute (NCI) · La Jolla, California and 25 other locations · NCT05896839

• Combining axitinib with nivolumab for advanced kidney cancer treatment

  This study is testing if adding a drug called axitinib to nivolumab can help people with advanced kidney cancer see better results than just using nivolumab alone.

  Recruiting Phase 2 Consorzio Oncotech · Brescia and 22 other locations · NCT05817903

• Using Nivolumab for Treating Resectable Mismatch Repair Deficient Endometrial Cancer

  This study is testing if the drug Nivolumab can help women with a specific type of endometrial cancer that can be surgically removed, to see if it leads to better treatment outcomes.

  Recruiting Phase 2 Yonsei University · Seoul · NCT05795244

• Combining cryoablation with immunotherapy for advanced melanoma

  This study is testing if freezing tumors along with two immunotherapy drugs can help people with advanced melanoma that hasn't improved with other treatments.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT05779423

• Combination therapy for advanced HER2-positive biliary tract cancer

  This study is testing a new combination treatment for people with advanced HER2-positive biliary tract cancer to see if it can help them live longer and feel better.

  Recruiting Phase 1/2 Yonsei University · Seoul · NCT05749900

• Combining nivolumab and relatlimab for treating melanoma that has spread to the brain

  This study is testing if combining two drugs, nivolumab and relatlimab, can help people with melanoma that has spread to the brain feel better and improve their treatment outcomes.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05704647

• Comparing two chemotherapy regimens for advanced HER2 negative gastric and esophageal cancer

  This study is testing if a new chemotherapy combination can help people with advanced HER2 negative stomach and esophageal cancer live longer compared to the standard treatment.

  Recruiting at 626 sites Phase 3 Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 801 other locations · NCT05677490

• Comparing standard therapy to immunotherapy for early stage Hodgkin lymphoma

  This study is testing if adding immunotherapy to standard chemotherapy helps people with early stage Hodgkin lymphoma live longer and stay cancer-free.

  Recruiting at 404 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 418 other locations · NCT05675410

• Combination treatment for advanced clear cell kidney cancer

  This study is testing a new combination of treatments for people with advanced clear cell kidney cancer to see if it is safe and effective.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05663710

• Targeted alpha-particle therapy for advanced melanoma

  This study is testing a new treatment for advanced melanoma that uses targeted radiation to see if it can help patients whose cancer can't be surgically removed.

  Recruiting at 15 sites Phase 1/2 Perspective Therapeutics · Orange, California and 15 other locations · NCT05655312

• Stopping nivolumab early for melanoma treatment

  This study is testing if stopping nivolumab early is safe and effective for patients with advanced melanoma who have responded well to their initial treatment.

  Recruiting Erasmus Medical Center · Rotterdam · NCT05652673

• Using memory-like natural killer cells with nivolumab and relatlimab for advanced melanoma after previous treatments

  This study is testing if a new type of immune cell treatment combined with two existing drugs can help people with advanced melanoma who haven't improved with previous therapies.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT05629546

• Fecal transplant plus nivolumab for people with advanced solid cancers that progressed on anti-PD-(L)1 therapy

  This will try a donor-derived fecal microbiota transplant together with nivolumab to see if it can control disease in people with advanced solid tumors who progressed on anti-PD-(L)1 drugs.

  Recruiting Asan Medical Center · Seoul · NCT05533983

• Combining CBL0137 with Ipilimumab and Nivolumab for Melanoma Treatment

  This study is testing a new drug called CBL0137 combined with standard melanoma treatments Ipilimumab and Nivolumab to see if it’s safe and helps people with advanced melanoma.

  Recruiting Early Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05498792

• Combining immunotherapy and chemoradiation for advanced cervical cancer

  This study is testing if adding two immunotherapy drugs to standard treatment can help people with advanced cervical cancer live longer without their disease getting worse.

  Recruiting at 6 sites Phase 2 Hospital Israelita Albert Einstein · Fortaleza, Ceará and 13 other locations · NCT05492123

• Combining Sarilumab with Other Treatments for Advanced Melanoma

  This study is testing a new combination of treatments for people with advanced melanoma to see if it helps them feel better and live longer.

  Recruiting at 4 sites Phase 2 NYU Langone Health · Los Angeles, California and 3 other locations · NCT05428007

• Combining axitinib and nivolumab for treating advanced mucosal melanoma

  This study is testing if a new combination of two cancer drugs, axitinib and nivolumab, can help people with advanced mucosal melanoma who haven't had treatment before feel better and live longer.

  Recruiting at 2 sites Phase 2 Memorial Sloan Kettering Cancer Center · Harrison, New York and 1 other locations · NCT05384496

• Combining 5-Azacytidine and Nivolumab for HPV-Associated Head and Neck Cancer

  This study is testing if combining a chemotherapy drug and an immunotherapy can help people with HPV-related head and neck cancer do better than using either treatment alone.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT05317000

• Combining nivolumab and ipilimumab for advanced colorectal cancer resistant to anti-PD1 treatment

  This study is testing if combining two cancer drugs, nivolumab and ipilimumab, can help people with advanced colorectal cancer that hasn't responded to other treatments.

  Recruiting at 9 sites Phase 2 GERCOR - Multidisciplinary Oncology Cooperative Group · Besançon and 8 other locations · NCT05310643

• Combining Nivolumab and ASTX727 for B-Cell Lymphoma Treatment

  This study is testing a new combination of two treatments, nivolumab and ASTX727, to see if it can help people with relapsed or hard-to-treat B-cell lymphoma feel better and live longer.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 8 other locations · NCT05272384

• CVM-1118 combined with Nivolumab for advanced liver cancer

  This study is testing if a new cancer drug called CVM-1118, when combined with Nivolumab, can help people with advanced liver cancer who haven't had success with other treatments.

  Recruiting at 5 sites Phase 2 TaiRx, Inc. · Kaohsiung City and 4 other locations · NCT05257590

• Vaccine combined with immune therapy for advanced lung cancer

  This study is testing a new vaccine combined with immune therapy to see if it can help people with advanced lung cancer live longer and feel better.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT05254184

• Combining PBF-1129 and Nivolumab for Advanced Lung Cancer Treatment

  This study is testing a new combination of two drugs, PBF-1129 and nivolumab, to see if it can help people with advanced lung cancer live longer and feel better.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05234307

• Low dose Nivolumab treatment for adults with HIV on antiretroviral therapy

  This study is testing if a low dose of Nivolumab can help adults with HIV on medication reduce the virus in their bodies and possibly stop their HIV treatment safely.

  Recruiting at 2 sites Phase 1/2 University of Melbourne · Melbourne, Victoria and 1 other locations · NCT05187429

• Combining cabozantinib and nivolumab to treat advanced melanoma and head and neck cancer

  This study is testing a combination of two cancer drugs, cabozantinib and nivolumab, to see if they can help people with advanced melanoma or head and neck cancer while also looking at how to better match treatments to patients based on their tumor characteristics.

  Recruiting at 211 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 231 other locations · NCT05136196

• Testing nivolumab with or without ipilimumab for recurrent endometrial cancer

  This study is testing if adding ipilimumab to nivolumab can help people with recurrent endometrial cancer live longer and feel better compared to just using nivolumab alone.

  Recruiting at 122 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 137 other locations · NCT05112601

• Combining nivolumab, ipilimumab, and cabozantinib for untreated kidney cancer that has spread to the brain

  This trial tests whether adding the oral drug cabozantinib to two immunotherapy medicines (nivolumab and ipilimumab) helps people with untreated renal cell carcinoma brain metastases live longer or have their brain tumors shrink.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05048212

• Combination treatment of brentuximab vedotin and nivolumab for relapsed Hodgkin lymphoma

  This study is testing if combining two treatments, brentuximab vedotin and nivolumab, can help people with relapsed Hodgkin lymphoma who haven't responded well to previous therapies.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT05039073

• Combining Certolizumab with Chemotherapy and Nivolumab for Treating Lung Cancer

  This study is testing if adding certolizumab to regular chemotherapy and nivolumab can help people with operable stage II-III lung cancer feel better by reducing inflammation and improving treatment results.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04991025

• Neoadjuvant treatment for operable non-small cell lung cancer using low-dose radiation and immunotherapy

  This study is testing a new treatment combining low-dose radiation and immunotherapy for patients with early-stage non-small cell lung cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 Brown University · Providence, Rhode Island · NCT04933903

• Neoantigen vaccine combined with nivolumab for liver cancer treatment

  This study is testing a personalized vaccine combined with a cancer drug to see if it can help people with liver cancer stay cancer-free after surgery.

  Recruiting Phase 2 National Cancer Centre, Singapore · Singapore · NCT04912765

• Combination of pomalidomide and nivolumab for treating virus-related cancers

  This study is testing a new combination of two medications, pomalidomide and nivolumab, to see if it can help adults with certain virus-related cancers that haven't improved with other treatments.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04902443

• Nivolumab treatment for nasopharyngeal cancer after platinum therapy

  This study is testing if Nivolumab, an immunotherapy drug, can help people with nasopharyngeal cancer who haven't responded to platinum chemotherapy.

  Recruiting at 4 sites Phase 2 Maria Sklodowska-Curie National Research Institute of Oncology · Bialystok and 3 other locations · NCT04875611

• Treatment for Primary Mediastinal Large B-cell Lymphoma with Antibody Therapy and ImmunoChemotherapy

  This study is testing a new combination of antibody therapy and chemotherapy to see if it helps people with untreated primary mediastinal large B-cell lymphoma feel better and improve their quality of life.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04745949

• Using telemonitoring to manage side effects in cancer patients receiving immunotherapy

  This study is testing if a telemonitoring system can help cancer patients receiving immunotherapy for melanoma, lung cancer, or renal cancer manage their side effects better by reporting their symptoms regularly.

  Recruiting at 3 sites Hospices Civils de Lyon · Bron and 9 other locations · NCT04605146

• Treatment for relapsed or refractory classical Hodgkin lymphoma using brentuximab vedotin and nivolumab

  This study is testing a combination of two drugs, brentuximab vedotin and nivolumab, to see if they can help people with classical Hodgkin lymphoma that has come back or didn’t respond to previous treatments.

  Recruiting at 5 sites Phase 2 City of Hope Medical Center · Duarte, California and 4 other locations · NCT04561206

• Blinatumomab versus blinatumomab plus nivolumab for first-relapse CD19+ B‑ALL

  This test sees if adding nivolumab to blinatumomab helps children and young adults (ages 1–30) with first-relapse CD19+ B‑cell acute lymphoblastic leukemia, including people with Down syndrome.

  Recruiting at 154 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 226 other locations · NCT04546399

• Comparing two treatment combinations for melanoma with brain metastases

  This study is testing two different treatment combinations for patients with melanoma that has spread to the brain to see which one helps them live longer without the disease getting worse.

  Recruiting at 303 sites Phase 2 SWOG Cancer Research Network · Birmingham, Alabama and 330 other locations · NCT04511013

• Combining cabozantinib with ipilimumab/nivolumab and TACE for liver cancer treatment

  This study is testing if combining cabozantinib with two immune therapies and a specific type of chemo can help people with liver cancer who can’t have surgery feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT04472767

• Innovative treatment combining photodynamic therapy and immunotherapy for malignant pleural mesothelioma

  This study is testing a new treatment that combines light therapy and immune therapy to see if it can help patients with advanced malignant pleural mesothelioma who haven't responded well to chemotherapy.

  Recruiting Phase 2 University Hospital, Lille · Lille · NCT04400539

• Comparing how often to give nivolumab or pembrolizumab for advanced cancers

  This study is testing if giving nivolumab or pembrolizumab less often can still help people with advanced cancers just as well as the usual schedule.

  Recruiting at 2 sites Phase 1 University of Chicago · Chicago, Illinois and 1 other locations · NCT04295863

• Vaccine treatment combined with immune therapy for a type of liver cancer

  This study is testing a new vaccine combined with immune therapy to see if it can help people with a specific type of liver cancer feel better and fight the disease.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT04248569

• Using Nivolumab to treat advanced skin cancer

  This study is testing if the drug Nivolumab, alone or with another drug called Relatlimab, can help people with advanced skin cancer feel better and improve their condition.

  Recruiting at 6 sites Phase 2 Salzburger Landeskliniken · Graz and 6 other locations · NCT04204837

• Long-term safety evaluation of nivolumab and other cancer therapies

  This study is testing the long-term safety of nivolumab alone and with other cancer treatments for patients who have responded well to previous therapies.

  Recruiting at 109 sites Phase 2 Bristol-Myers Squibb · Huntsville, Alabama and 409 other locations · NCT03899155

• Combination therapy for advanced sarcoma using three different treatments

  This study is testing a combination of three treatments for advanced sarcoma to see if they can help patients live longer without their cancer getting worse.

  Recruiting Phase 2 Sarcoma Oncology Research Center, LLC · Santa Monica, California · NCT03886311

• Combining immunotherapy and targeted therapy for rare bladder tumors

  This study is testing a new combination of treatments for people with rare bladder tumors that have spread, to see if it helps them live longer and feel better.

  Recruiting at 222 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 581 other locations · NCT03866382

• Combination treatment with nivolumab and entinostat for children with high-risk cancers

  This study is testing a new combination of two drugs, nivolumab and entinostat, to see if it can help children and teens with tough-to-treat cancers feel better and have better outcomes.

  Recruiting at 14 sites Phase 1/2 University Hospital Heidelberg · Randwick, New South Wales and 13 other locations · NCT03838042

• Using nivolumab to treat patients with autoimmune disorders and advanced cancer

  This study is testing if nivolumab can safely help people with autoimmune disorders who also have advanced cancer by looking at how well it works and what side effects it might cause.

  Recruiting at 40 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 51 other locations · NCT03816345

• Pre-operative treatment for breast cancer using nivolumab and novel immunotherapies

  This study is testing whether a new combination of immunotherapy treatments can help boost the immune response in patients with early-stage breast cancer before surgery.

  Recruiting Phase 2 The Netherlands Cancer Institute · Amsterdam · NCT03815890

• Treatment for recurrent and refractory solid tumors using engineered T-cells and nivolumab

  This study is testing a new treatment using specially designed T-cells and a drug called nivolumab to see if it can help people with tough-to-treat solid tumors.

  Recruiting at 21 sites Phase 1/2 Immatics US, Inc. · Stanford, California and 20 other locations · NCT03686124

• Evaluating nivolumab with isolated limb perfusion for melanoma patients

  This study is testing if combining the immunotherapy drug nivolumab with a special treatment for the arm or leg can help people with advanced melanoma feel better and stay safe during the treatment.

  Recruiting at 2 sites Phase 1/2 Vastra Gotaland Region · Amsterdam and 3 other locations · NCT03685890

• Combining nivolumab and ruxolitinib for treating relapsed Hodgkin lymphoma

  This study is testing if combining two drugs, nivolumab and ruxolitinib, can safely help people with relapsed Hodgkin lymphoma feel better.

  Recruiting at 3 sites Phase 1/2 Big Ten Cancer Research Consortium · Chicago, Illinois and 5 other locations · NCT03681561

• Nivolumab treatment for advanced basal cell carcinoma

  This study is testing if the drug nivolumab, alone or with other medications, can help people with advanced basal cell carcinoma that can't be removed by surgery.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT03521830

• Using Nivolumab after Half-Matched Bone Marrow Transplant for Sarcoma

  This study is testing if a new drug called Nivolumab can help prevent or delay the return of high-risk sarcomas in children and adults after they receive a special type of bone marrow transplant.

  Recruiting at 3 sites Phase 1/2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · St. Petersburg, Florida and 3 other locations · NCT03465592

• Combining immunotherapy and radiotherapy for melanoma brain metastases

  This study is testing if combining two immune therapies with targeted radiation can help people with melanoma that has spread to the brain feel better and live longer.

  Recruiting at 8 sites Phase 2 Melanoma Institute Australia · Sydney, New South Wales and 8 other locations · NCT03340129

• Using Nivolumab to treat EBV-positive lymphoproliferative disorders and non-Hodgkin lymphomas

  This study is testing if a new drug called Nivolumab can help people aged 12 and older with certain types of lymphomas that are linked to the Epstein-Barr Virus and haven't improved with other treatments.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03258567

• Combination treatment for advanced soft tissue sarcoma

  This study is testing a new combination of treatments using Trabectedin, Ipilimumab, and Nivolumab to see if it can help people with advanced soft tissue sarcoma who have already received other treatments.

  Recruiting Phase 1/2 Sarcoma Oncology Research Center, LLC · Santa Monica, California · NCT03138161

• Short-term immunotherapy for early-stage colon cancer

  This study is testing a new short-term immunotherapy treatment for early-stage colon cancer to see if it can help patients stay cancer-free after surgery.

  Recruiting at 4 sites Phase 2 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT03026140

• Vaccine treatment for relapsed or refractory blood cancers

  This study is testing a new vaccine treatment for people with relapsed or hard-to-treat blood cancers to see if it can help them feel better and live longer.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT03017820

Quick answers

How many clinical trials of Nivolumab are recruiting right now?

149, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 50 countries. The most sites are in United States (88 trials), Australia (17 trials), France (17 trials), Germany (14 trials), Canada (12 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 73, Phase 1/2: 24, Phase 1: 19, Phase 3: 12. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →